Stock is trading near all-time lows as of 7/6/2020.
Expansive gene therapy pipeline with FDA orphan designation of OCU400.
Insider purchases in recent months and no reported sales.
Discontinued phase trial of drug candidate OCU300.
On June 1, the company discontinued their Phase 3 trial ...
